KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Invested Capital (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Return on Invested Capital for 10 consecutive years, with 0.15% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Invested Capital fell 8.0% to 0.15% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.15%, a 8.0% decrease, with the full-year FY2025 number at 0.16%, down 10.0% from a year prior.
  • Return on Invested Capital was 0.15% for Q4 2025 at Halozyme Therapeutics, down from 0.5% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.5% in Q3 2025 to a low of 0.06% in Q2 2022.
  • A 5-year average of 0.22% and a median of 0.16% in 2023 define the central range for Return on Invested Capital.
  • Biggest YoY gain for Return on Invested Capital was 55bps in 2021; the steepest drop was -33bps in 2021.
  • Halozyme Therapeutics' Return on Invested Capital stood at 0.11% in 2021, then rose by 16bps to 0.13% in 2022, then grew by 24bps to 0.16% in 2023, then skyrocketed by 40bps to 0.23% in 2024, then tumbled by -34bps to 0.15% in 2025.
  • Per Business Quant, the three most recent readings for HALO's Return on Invested Capital are 0.15% (Q4 2025), 0.5% (Q3 2025), and 0.47% (Q2 2025).